RECRUITING Phase 1 / Phase 2 ClinicalTrials.gov

Study of ABS-201 Evaluating Single and Multiple Ascending Doses in Adults With and Without Androgenetic Alopecia

Sponsor: Absci Pty Ltd. • ClinicalTrials.gov ID: NCT07317544

Registry updated: 2026-09-03

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Description

This is a first-in-human study of ABS-201, a new investigational medicine, in healthy adult men and women. Its main purpose is to find out whether ABS-201 is safe and well tolerated, as well as to understand how the body processes it and how it affects related biological markers. ABS-201 is being developed as a possible treatment for androgenetic alopecia (male- and female-pattern hair loss); its effect on hair growth has not yet been established. The study has two parts: in the single ascending dose (SAD) part, healthy adults receive one intravenous dose of ABS-201 or placebo; and in the multiple ascending dose (MAD) part, participants (including men with androgenetic alopecia) receive several subcutaneous doses of ABS-201 or placebo. The MAD part also evaluates the effect of ABS-201 on hair growth. The main questions it aims to answer are: What medical problems, if any, do participants experience when taking a single dose or many doses of ABS-201? How does the medication, ABS-201, compare to placebo (a look alike substance that does not contain any medication). Participants who qualify for the trial will receive either ABS-201 or a placebo, and visit the study clinic for scheduled checkups and tests for approximately 12 months in the single ascending dose (SAD) part and approximately 18 months in the multiple ascending dose (MAD) part. In the MAD part, participants receive repeated subcutaneous doses.

Interventions

SAD IV Dose 1 - 150mg ABS201 IV Single Dose (Drug)
ABS-201 is an IgG1 monoclonal antibody developed to specifically target the prolactin receptor (PRLR)
Placebo IV (Drug)
Matching placebo
ABS-201 SC Multiple Doses (Drug)
Multiple doses of ABS-201 for Subcutaneous injection
Placebo SC Injection (Drug)
Subcutaneous Placebo injection for MAD arms

Eligibility criteria

Inclusion Criteria (Major): * Participants must be overtly healthy, as determined by medical evaluation, which includes a review of medical and surgical history, physical examination, and a 12-lead ECG. * Must have normal ranges for hematology, clinical chemistry, coagulation tests, and urine analysis parameters * Participants, male and female, must be willing to avoid pregnancy for the duration of the trial. * Participants must be capable of giving signed informed consent * Participants must have no signs or symptoms of active or latent tuberculosis (TB), Additional Inclusion criteria for patients with AGA: * Diagnosis of AGA with a Norwood-Hamilton Scale III vertex to V pattern. * Willing to clip target hair area for analysis and avoid scalp pigmentation products. * Willingness to maintain approximately the same hair length at each study visit Exclusion Criteria (Major): * History or presence of cancer, except for basal cell carcinoma or cervical dysplasia successfully treated with no recurrence for ≥90 days before screening. * History of liver disease, Gilbert's syndrome, or abnormal liver function tests (e.g., ALT, AST, or bilirubin \> ULN) at screening * Systolic blood pressure ≤90 or ≥140 mmHg, diastolic BP ≤40 or ≥90 mmHg, pulse rate \<40 or \>100 bpm * Positive test for HIV, hepatitis B (HBV), or hepatitis C (HCV). * Recent blood donation * Any clinically significant psychiatric disorder * Pregnant or breastfeeding females or those planning pregnancy during the study. * History of postpartum depression, perimenopausal mood instability, or estrogen withdrawal syndrome Additional Exclusion criteria for participants with AGA undergoing hair assessments: • Prior use of hair loss treatments: 1. Topical minoxidil within 3 months before screening. 2. Oral minoxidil other hair growth stimulators within 6 months before screening. 3. Finasteride within 6 months before screening 4. Dutasteride within 12 months before screening. * Use of GLP-1 receptor agonists (e.g., semaglutide, liraglutide, dulaglutide, exenatide, tirzepatide, or similar agents) within 3 months prior to screening * History of hair transplantation or other major scalp procedures or planned procedures during the study. * Use of hair extensions, wigs, hairpieces, weaves, or any other artificial hair enhancement methods within 30 days prior to screening and throughout the study. * History of clinically significant dermatologic disease of the scalp that could interfere with hair assessments or target area imaging

Conditions

Androgenetic Alopecia (AGA) Healthy Volunteers - Male and Female

Locations

Momentum Darlinghurst — Sydney, New South Wales, Australia
Nucleus Network Brisbane — Brisbane, Queensland, Australia
Sinclair Dermatology — Melbourne, Victoria, Australia
Nucleus Network — Melbourne, Victoria, Australia

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record

Accelerate Your Clinical Trial Recruitment